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A silver-hydroxyapatite nanocomposite has been obtained by a colloidal chemical route and subsequent reduction process in
H2/Ar atmosphere at 350◦C. This material has been characterized by TEM, XRD, and UV-Visible spectroscopy, showing the
silver nanoparticles (∼65 nm) supported onto the HA particles (∼130 nm) surface without a high degree of agglomeration. The
bactericidal eﬀect against common Gram-positive and Gram-negative bacteria has been also investigated. The results indicated
a high antimicrobial activity for Staphylococcus aureus, Pneumococcus and Escherichia coli, so this material can be a promising
antimicrobial biomaterial for implant and reconstructive surgery applications.
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1. Introduction
The occurrence of bone fractures due to the growing number
of traﬃc accidents, as well as the musculoskeletal conditions
requiring reconstructive surgery derived from the increase in
the human life expectancy, has led to an increasing number
of people in the world having at least one orthopedic or
dental implant. In addition to the considerable impact on
the health and quality of life that these types of surgery have
on the population, they impose an important burden for the
economy of countries. Only in the United States, the number
of orthopedic procedures performed each year—including
knee arthroplasty, total and partial hip replacement, and
spinal fusion—increased by nearly 25 percent between 1997
and 2005, climbing from 822 000 to 1.3 million, according to
the latest News and Numbers summary from the Agency for
Healthcare Research and Quality [1]. The same report finds
also that the costs related to hospital stays for orthopedic
procedures totalled $31.5 billion. It has also been estimated
that 2 million new dental implants are performed every year
[2]. Therefore the need for reliable and economically feasible
biomaterials for healing fractures or treating musculoskeletal
diseases has increased in the last years.
Hydroxyapatite (HA, Ca10(PO4)6(OH)2) is the main
mineral component of bone, and its synthetic form is one of
the most widely used biomaterials for reconstruction of the
skeleton due to the lack of local or systemic toxicity together
with its osteoconductive properties [3–5]. It is used as an
implant material both in its bulk mainly porous form, for
filling in or reconstructing bone defects, and as a thin coating
on metals, titanium and CoCrMo alloys, for hip, knee, and
dental prostheses. Although success rates of these kinds of
implants are dependent on bone-implant osteointegration,
the success and long-term survival of the implants are also
dependent on the prevention of bacterial infection after
implant placement.
Despite the use of perioperative antimicrobial prophy-
laxis and laminar flow operating rooms, the infection rates
associated with prosthetic joints range between 1% and
9%, depending on the type of implant [6]. Although the
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infection-associated implant failures occur less frequently
than aseptic ones, they are the second reason for revision
surgery in the case of total hip replacements [7] and represent
the most devastating complication with high morbidity and
elevated medical cost. Moreover, infection rates after surgery
revision are 40% higher than after primary replacement
[8]. Studies on orthopaedic patients revealed that the
estimated average total direct cost associated with an infected
case ranges between $15 000 and $30 000—an increase of
approximately 3 times than the initial intervention—and
shown that the patients spent on average 14 extra days in the
hospital after readmission [9]. In the case of dental implants,
complications derived from an implant-associated infection
do not usually require patient hospitalization, but lead to
a detriment in the patient quality of life and satisfaction
because it is one of the reasons for early failures by lack of
osseointegration and the major cause of late failures [10].
Therefore, eﬃcient prevention of implant-associated
infections to avoid surgical revisions and expensive and
long hospital stays that increase the patient morbidity is of
paramount importance. One common and accepted strategy
to treat and prevent infections associated with orthopedic
implants is to deliver antibiotics in a controlled manner at the
site of implantation in order to administer high local doses
without exceeding the systemic toxicity of these drugs [11–
13]. Antibiotic release has been achieved using a wide variety
of biocompatible materials in the form of coatings or beads.
Some of these materials are polymers (polyurethane, poly-
hydroxylalkanoates, polymethylmethacrylate (PMMA), poly
L-lactic acid (PLA), poly(lactic-co-glycolic) acid (PLGA),
etc.), and synthetic hydroxyapatite (HA) [14–16]. Although
controlled drug delivery has been shown for nonbiodegrad-
able polymers, such as PMMA, its eﬀectiveness, however,
is strongly dependent on the antibiotic release profile from
the polymer, which is a function of the chemical similarity
between the drug and the polymer, as well as of the physical
properties of the polymer itself [14, 15, 17]. Moreover, the
nonbiodegradable polymers do not resorb and require a
subsequent operation for removal.
The biodegradable antibiotic-loaded polymer coatings,
such as PLA or PLGA, are able to resorb, so it overcomes this
latter disadvantage, but its high hydrophobicity is another
important drawback, since it places practical constraints on
formulating devices with suﬃcient antibiotic loading and
dispersion for reliable delivery of antimicrobials [14].
A good approach to the local treatment of implant-
associated infections is the use of HA coatings for antibiotics
delivery, exploiting the osteoconductive properties of this
material. However, the loading and release rate is strongly
dependent on the acidic or basic character of antibiotics.
Acidic antibiotics are incorporated with greater eﬃciency
than basic antibiotics because of the calcium-chelating prop-
erties of the carboxylate groups. However, through calcium-
carboxylate chelating interactions, the acidic antibiotics are
retained to a greater extent relative to the basic antibiotics
[15]. This fact imposes certain limitations in cases that
require the use of acidic antibiotics, for example amoxicillin.
The capacity of certain bacterial strains to develop resis-
tance against antibiotics has aroused an increasing interest
for the controlled delivery of other antibacterial agents with a
broader activity and low incidence of resistance, such metals
like silver or zinc, being an alternative strategy to avoid the
formation of adhesive bacterial films [18]. The antibacterial
properties of silver at low concentrations over a wide range of
pathogens, including the common bacterial strains involved
in implant-associated infections as well as the lack of toxicity
for the mammalian cells, are well known [19–24].
Most silver-containing antimicrobial biomaterials consist
of either elemental silver or Ag+ (silver salts or silver com-
plexes) incorporated into organic (polymers) or inorganic
(bioglasses and HA) matrices. While the in vitro antimi-
crobial activity of silver-containing polymers (polyamides,
polyurethane, and PMMA) and bioglasses has been exten-
sively studied [25–28], the bactericide action of Ag-HA
materials has been reported in less extension. Recently, Ag-
loaded HA composites obtained by ion-exchange methods
(sol-gel or coprecipitation) have been reported [29–32].
These routes involve the silver substitution for calcium,
resulting in a Ca-deficient hydroxyapatite. The antimicrobial
response of these materials is good, but they have two main
drawbacks: (i) the depletion of calcium could have negative
eﬀects on the structural stability of nano HA [31] as well
as on its osteoconduction ability [32]; (ii) a rapid release of
silver, depending on the pH, can take place. These facts have
brought out an increasing interest on silver nanoparticles as
bactericidal reservoir due to their low solubility in aqueous
media. Studies on nanosilver-loaded polymer films reveal
that the duration of silver release is strongly dependent on
the total amount of silver nanoparticles [19]. The biocide
activity of colloidal silver nanoparticles is influenced by
their size—the smaller the particles, the greater antimi-
crobial eﬀect [22]—however, the aggregation problems of
nanoparticles are well known. A common solution to avoid
this disadvantage is to support the nanoparticles on the
surface of diﬀerent substrates. Despite the potential clinical
applications of nAg-HA composites due to the combination
of osteoconductive and bactericide properties, there are few
examples in the literature of silver nanoparticles supported
onto hydroxyapatite particles. These materials have been
obtained by cosputtering of silver and hydroxyapatite to form
coatings on titanium surfaces [33], and by in situ reduction
of silver cations on the surface of HA particles [34]. In the
present work, a simple and low-cost method to support
silver on the surface of hydroxyapatite to obtain a nano-nano
hybrid composite, containing 1 wt% of elemental silver, with
antimicrobial activity is presented.
2. Materials andMethods
2.1. Preparation. The preparation method comprises two
steps: (i) synthesis of HA nanoparticles by a sol-gel pro-
cessing route, and (ii) precipitation of Ag2O nuclei from
silver nitrate aqueous solution and further reduction with
an Ar/H2 gas mixture at low temperature to obtain silver
nanoparticles attached onto nano-HA.
The precursors employed in the HA nanoparticles
were triethylphosphite (98%, Aldrich) and calcium nitrate
Journal of Nanomaterials 3
(b)
(a)
In
te
n
si
ty
0 20 40 60
2θ (degrees)
Figure 1: XRD patterns corresponding to diﬀerent stages of HA
synthesis: (a) amorphous dry gel; (b) crystallization at 550◦C.
tetrahydrate (≥99%, Fluka). Aqueous solutions 3 M were
prepared for each precursor in order to obtain a final Ca/P
molar ratio of 1.67. The phosphorous solution was added
dropwise to the calcium solution under vigorous stirring
while maintaining the temperature at 65◦C and pH = 8.
The pH was controlled by addition of NH4OH (28% w/w,
Fluka) aqueous solution. The resulting colloidal suspension
was stirred at 70◦C for two hours and then aged at room
temperature for 24 hours to obtain white and viscous gel. The
gel was dried in a vacuum chamber at 100◦C until the solvent
was completely removed. The dry powder was ground and
calcined at 550◦C for 2 hours. A well-crystallized HA powder
was obtained.
In order to prepare the nAg-HA composite 5 g of the HA
powder obtained in the previous synthesis were suspended
in 50.55 mL of distilled water (9 wt% of solids loading).
Subsequently, the suspension pH was adjusted to 5 by adding
dropwise a 0.1 N HNO3 aqueous solution under stirring at
60◦C. Then, 10 mL of a 4.7 × 10−2 M AgNO3 aqueous solu-
tion were added to obtain an nAg-HA composite containing
1 wt% of metallic silver. Under continuous stirring, the pH
was adjusted to 9 by adding dropwise a 1 M NaOH aqueous
solution to precipitate Ag+ cations as Ag2O, according to
the potential-pH diagram in aqueous solution for silver
[35]. The suspended white powder slowly turned to gray,
indicating the presence of Ag2O precipitation nuclei. Finally,
the suspension was filtered and washed twice with distilled
water at 60◦C. The resulting powder was dried at 60◦C and
calcined at 350◦C for 2 hours in a gas mixture of Ar/H2 90/10
in order to reduce the silver oxide to metallic silver, yielding
a pale brown powder. All steps of this synthesis were carried
out in absence of light to avoid the spontaneous reduction of
silver cations to elemental silver.
2.2. Characterization Techniques. X-ray powder diﬀraction
(XRD) patterns were registered using a Bruker D8 Advance
diﬀractometer with a Cu Kα radiation source at a scan speed
of 0.5◦/min and a step scan of 0.02◦.
The powder particle size distribution was carried out in
a instrument Coulter? LS 13320 using laser radiation (λ =
750 nm).
Transmission electron microscopy images were recorded
on a Jeol 2000 FXII instrument operating at 200 kV.
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Figure 2: Particle size distribution of hydroxyapatite powder.
UV-vis spectroscopy was performed using a Cary 4000
uv-vis spectrophotometer.
2.3. Antimicrobial Activity. To investigate the bactericidal
eﬀect of the nAg-HA composite, two types of tests were
performed as follows.
(i) A qualitative diﬀusion disk test using 105 colony
forming units (CFUs) of the Staphylococcus aureus
(Sa), Pneumococcus (Pn), and Escherichia coli (Ec).
They were cultured on LB agar plates. Pellets of
0.05 g, 8 mm in diameter, pressed at 100 MPa of
HA (as control) and of nAg-HA composite were
located at the center of the Petri plate. The plates
were incubated for 24 hours at 37◦C. The microbial
inhibition zone was observed under optical micro-
scope. The inhibition zone size around three pellets
corresponding to the nAg-HA sample and the control
for the diﬀerent bacterial cultures was averaged.
(ii) A quantitative analysis using 105 CFU of a Gram-
negative bacterium Ec strain B which were cultured
on LB agar plates containing diﬀerent concentrations
of composite, 1, 5, and 10 mg/cm3, corresponding
to 10, 50, and 100 μg/cm3 of silver nanoparticles,
respectively. Silver-free HA LB agar plates cultured
under the same conditions were used as a control.
The plates were incubated for 24 hours at 37◦C, and
the numbers of colonies were counted. The counts on
the three plates corresponding to each sample were
averaged.
3. Results and Discussion
The crystallization process of the hydroxyapatite powder is
shown in Figure 1. The granulometric analysis (Figure 2)
revealed a stretch size distribution with an average size (d50)
of 137 nm, in agreement with the TEM images of the powder
shown in Figure 3.
The XRD pattern of the resulting HA-nAg powder
is shown in Figure 4. The reflections at 38.1◦ and 44.3◦
correspond to metallic silver. No other phases but HA were
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Figure 3: TEM image showing the size and morphology of the HA
nanoparticles synthesized.
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Figure 4: XRD pattern corresponding to the 1 wt% Ag-containing
HA composite after reduction treatment ( Ag (0)).
detected, which indicates that destabilization or dissolution
of hydroxyapatite has not taken place during the Ag nanopar-
ticles synthesis.
The average particle size of silver, calculated from the
Scherrer formula, was found to be 65 nm. TEM images
show in Figure 5 a size distribution of globular-shape silver
particles that range between less than 20 nm and 100 nm.
The majority of larger silver particles occur onto aggregates
of HA particles. This fact could be related with a partial
destabilization of HA particles in aqueous suspension that
gives rise to the formation of aggregates, where the growth of
Ag2O nuclei could be favored. It is well known that the size of
the particles formed from a solution is inversely proportional
to the number of small precipitation nuclei, so the greater the
number of these, the smaller the particles obtained [36]. The
decrease of the specific surface of HA aggregates can aﬀect the
distribution of the precipitation nuclei at these sites, leading
to the growth of the particles. On the other hand, bigger Ag
particles can also be formed by coalescence of smaller ones
during the reduction process.
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Figure 5: (a) TEM image showing the size distribution of Ag
nanoparticles; (b) high magnification TEM image showing n-Ag
particles less than 20 nm attached on the HA surface.
The pale brown color of the Ag-HA powder is due
to the excitation of surface plasmon vibrations of silver
nanoparticles on the HA surface. The UV-VIS spectrum is
shown in Figure 6. The broad band centered at 450 nm agrees
with a size distribution due to the partial aggregation of
silver nanoparticles [34]. The colloidal silver solutions are
yellow when the nanoparticles are well dispersed. However,
if the particles are close enough, there is an overlap of the
surface plasmon vibrations between neighboring particles
and results in changes in the optical properties. This can
occur due to the aggregations of the silver nanoparticles,
leading to an eﬀective decrease in the average interparticle
distance. The absence of higher-wavelength features (see
Figure 6) indicates the lack of anisotropy of the silver
nanoparticles, in good agreement with the TEM images.
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Figure 6: UV-vis spectrum of the Ag-HA powder showing the
surface plasmon band of silver nanoparticles.
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Figure 7: Number of E. coli colonies as a function of the
concentration of silver nanoparticles expressed as a percentage of
the number of colonies grown on silver-free control plates.
The diﬀusion disk tests showed, in all the cases, a
similar exclusion area that appears only around the nAg-HA
composite pellets, as it is reported in Table 1. These results
show that a silver concentration of 10000 ppm is ended up
in toxicity for common Gram-positive and Gram-negative
bacteria. Figure 7 shows the number of bacterial colonies
grown on LB plates containing 1, 5, and 10 mg/cm3 of nAg-
HA composite and pure HA as control, when approximately
105 CFU were cultured in the plates. After 24 hours, the
presence of silver nanoparticles at a concentration of 10 and
50 μg/cm3 inhibited the bacterial growth by 62% and 88%,
respectively, while a concentration of 100 μg/cm3 caused
100% inhibition of bacterial growth.
These results show a strong bactericidal eﬀect against
Sa, Pn, and Ec. In the particular case of Gram-negative
bacterium E. coli, it is slightly lower than colloidal silver
nanoparticles systems [20] with an average particle size
between 10 and 20 nm. However, the nanocomposite powder
posseses an interesting advantage: it can be easily handled
and shaped into pellets or sponges without special care
Table 1: Diﬀusion disk test of HA-nAg pellets, containing
10000 ppm of Ag, against Staphylococcus aureus, Pneumococcus, and
Escherichia coli after 24 hours at 37◦C.
S. aureus Pneumococcus E. coli
Inhibition zone
17 17.5 18
diameter (±0.5 mm)
to avoid the typical agglomeration problems related to the
colloidal systems of nanoparticles.
4. Conclusions
In summary, we have described a simple and low-cost
method to obtain a HA-Ag nanocomposite powder with
bactericidal properties. TEM, XRD, and UV-vis techniques
have showed the presence of silver nanoparticles (∼65 nm)
attached on the hydroxyapatite particles surface without
a high degree of agglomeration. The bactericidal activity
results show that this nanocomposite is strongly active
against some of the most common Gram-positive and Gram-
negative bacterial strains, so it can be considered as an
antimicrobial biomaterial that can be used in implant and
reconstructive surgery applications.
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